Form 8-K

8-K — Spectral AI, Inc.

Accession: 0001213900-26-088341

Filed: 2026-08-12

Period: 2026-08-11

CIK: 0001833498

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0301807-8k_spectral.htm (Primary)

EX-99.1 — PRESS RELEASE ISSUED BY SPECTRAL AI, INC. ON AUGUST 11, 2026 (ea030180701ex99-1.htm)

GRAPHIC (ea030180701_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0301807-8k_spectral.htm · Sequence: 1

false

0001833498

2026-08-11

0001833498

MDAI:CommonStockParValue0.0001PerShareMember

2026-08-11

0001833498

MDAI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf2.75PerShareMember

2026-08-11

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date

of Report (Date of earliest event reported): August 11, 2026

SPECTRAL AI, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-40058

85-3987148

(State

or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S.

Employer

Identification No.)

2515 McKinney Avenue, Suite 1000

Dallas,

Texas

75201

(Address

of principal executive offices)

(Zip

Code)

(972)

499-4934

(Registrant’s

telephone number, including area code)

Not

Applicable

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of

the following provisions:

☐

Written communication pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencements communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbols

Name

of each exchange on which registered

Common Stock, par value $0.0001 per share

MDAI

The

Nasdaq Stock Market LLC

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $2.75 per share

MDAIW

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

August 11, 2026, Spectral AI, Inc. (the “Company”) reported its financial results for the quarter ended June 30, 2026. Additionally,

the Company hosted a conference call on August 11, 2026, at 5:00 pm Eastern Time with financial analysts to discuss the Company’s

financial results and other business matters. This event will be available for replay on the Company’s website: https://investors.spectral-ai.com/news-events/events.

Item

7.01. Regulation FD Disclosure.

August 11, 2026, the Company issued a press release reporting its financial results for the quarter ended June 30, 2026, as discussed

above. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The

information in this Item 7.01 to this Current Report on Form 8-K, and in Exhibit 99.1 furnished herewith, shall not be deemed

to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing

under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such

a filing.

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release issued by Spectral AI, Inc. on August 11, 2026.

104

Cover Page Interactive

Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Dated:

August 12, 2026

SPECTRAL AI, INC.

By:

/s/

Vincent S. Capone

Name:

Vincent S. Capone

Title:

Chief Executive Officer

EX-99.1 — PRESS RELEASE ISSUED BY SPECTRAL AI, INC. ON AUGUST 11, 2026

EX-99.1

Filename: ea030180701ex99-1.htm · Sequence: 2

Exhibit 99.1

Spectral

AI Announces 2026 Second Quarter Financial Results

Company

Continues to Advance Towards First Commercial Sales of

the

DeepView® System for Burn Indication

Strong

Cash Position of $14.0 Million at June 30, 2026

DALLAS,

TX – August 11, 2026 – Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an

artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today

announced financial results for the second quarter ended June 30, 2026 (“Q2 2026”).

“Spectral

AI has entered the second half of 2026 with tremendous momentum and a clear sense of purpose,” said Vincent Capone, Chief Executive

Officer of Spectral AI. “The receipt of De Novo clearance from the U.S. Food and Drug Administration (“FDA”) for our

DeepView® System for burn indication has cleared us to achieve our first commercial sales by year end 2026. We have made significant

strides in the first half of this year by strengthening our leadership team, advancing our relationships with government and commercial

partners, and fortifying our balance sheet. As we look ahead, we are excited by the scale of the opportunity before us. We remain strongly

focused on our vision of supporting clinicians by bringing immediate, objective, and data-driven wound assessments that improve patient

outcomes, and on the commercial delivery of our advanced, novel artificial intelligence technology to the marketplace.”

Select

Business Highlights

● In

May 2026, received FDA clearance for the DeepView System for Burn Indication; with this classification,

Spectral AI is now authorized to commence commercial distribution activities in the United

States.

● In

March 2026, awarded $31.7 million of advanced funding from the Biomedical Advanced Research

and Development Authority (“BARDA”) to accelerate and support additional development

and procurement for the DeepView System.

● Following

the receipt of FDA clearance for the DeepView System, drew $6.5 million under our existing

credit facility with Avenue Capital Group, providing non-dilutive capital to further strengthen

the Company’s balance sheet.

● Expanded

leadership team in advance of commercial activities, including the appointments of David

McGuire as Chief Financial Officer and Darcy Bajko as Chief Commercial Officer.

● Completed

all remaining milestones under our Department of Defense contract for the DeepView System

handheld device, contracted through the Medical Technology Enterprise Consortium (“MTEC”),

including the delivery of a fully functioning prototype device.

● Commenced

label expansion of the DeepView System to include heads, hands and feet through an extended

study based in the United Kingdom.

Anticipated

Operational and Commercial Milestones

● Generate

first-ever commercial sales of the DeepView System in the U.S. by year end 2026.

● Complete

UKCA authorization label expansion to reflect the FDA approved DeepView System for sales

in either the United Kingdom, Australia, or Gulf Cooperation Council countries by year end

2026.

● Initiate

Triage and Treatment Outcome Study in Q4 2026 to demonstrate that the DeepView System’s

wound assessments improve surgical precision and accelerate treatment decisions, leading

to a better overall patient care journey and reduced length of stay.

2026

Second Quarter (“Q2 2026”) Financial Results Overview

All

comparisons for Q2 2026 and the six months ended June 30, 2026 (“YTD 2026”) are to the comparable periods ended June 30,

2025 unless otherwise stated.

Research

& Development Revenue

Research

& Development revenue for Q2 2026 was $3.5 million compared to $5.1 million. The decline reflects the anticipated reduction in reimbursed

costs under the Company’s Project BioShield contract with BARDA (the “BARDA PBS Contract”) following FDA clearance

of the DeepView System, as the remaining scope of work narrowed to specific development projects. It also reflects the cost-share provisions

of the follow-on development phase of that contract, under which the Company funds a portion of the development costs it incurs. Revenue

from the Company’s other U.S. government contracts also declined as the Company completed performance under its MTEC contract.

“We

view the triggering of the cost-share component under our contract with BARDA as an indicator of program maturity,” said David

McGuire, Spectral AI’s Chief Financial Officer. “It reflects the completion of the core development work of the DeepView

System and FDA clearance of the device, while maintaining alignment with BARDA on the features expected to support commercial value.

We are very excited to enter this next promising phase towards commercial revenues.”

For

YTD 2026, Research & Development revenue was $7.5 million compared to $11.8 million. The decline reflects the same reduction in reimbursed

costs under the BARDA PBS Contract. This was partially offset by an increase in revenue from awards and work performed under the Company’s

other U.S. government contracts, primarily related to work on the Company’s handheld device.

Gross

Margin

Gross

margin for Q2 2026 was 31.6%, down from 45.2%. The decline reflects the cost-share provisions of the follow-on development phase of the

BARDA PBS Contract described above, under which the Company continues to incur development costs that are not fully reimbursable. A slightly

lower realized margin on the Company’s fixed-fee MTEC contract also contributed to the reduction.

For

YTD 2026, gross margin was 41.8%, down from 46.4%. The decline primarily reflects the lower proportion of costs billed under the follow-on

development phase of the BARDA PBS Contract. This was partially offset by the higher gross margin realized in the first quarter of 2026,

prior to the commencement of that phase.

Operating

Expenses

we transition from mainly development activities to mixed development and commercial activities, we have disaggregated our reporting

of G&A costs to break out development, sales and marketing and administrative costs in order to provide investors with clearer and

more meaningful visibility of our evolving cost base.

Operating

expenses in Q2 2026 were $5.4 million, up 23.2% from $4.4 million. General and administrative expenses rose $0.5 million, primarily due

to equity awards granted in the second quarter of 2026. Selling and marketing activities rose $0.3 million ahead of first commercial

sales, including a third-party pricing study. Research and development activities rose $0.2 million.

For

YTD 2026, operating expenses were $9.4 million, up 11.3% from $8.5 million. Non-revenue generating research and development activities

rose $0.5 million. General and administrative expenses rose $0.3 million, as higher stock-based compensation was partially offset by

lower consultant fees. Selling and marketing activities rose $0.2 million.

Total

Other (Expense) / Income

Total

other income in Q2 2026 was $0.3 million compared to other expense of $(5.9) million. The change was due largely to the fair value of

the Company’s warrant liability, which was a benefit of $0.7 million compared to an expense of $(5.4) million.

For

YTD 2026, total other expense was $(1.1) million compared to other expense of $(2.0) million. The change primarily relates to the fair

value of the Company’s warrant liability, which was an expense of $(0.3) million compared to an expense of $(1.2) million.

Net

(Loss) Income

Net

loss for Q2 2026 was $(4.2) million, or $(0.13) per basic and diluted share, compared to net loss of $(8.0) million, or $(0.31) per basic

and diluted share. The improvement was due primarily to the change in the fair value of the Company’s warrant liability noted above,

partially offset by lower gross profit and higher operating expenses.

For

YTD 2026, net loss was $(7.6) million, or $(0.24) per basic and diluted share, compared to net loss of $(5.1) million, or $(0.21) per

basic and diluted share. The increase primarily reflects lower gross profit and higher operating expenses, partially offset by lower

total other expense.

Adjusted

EBITDA

Adjusted

EBITDA, a non-GAAP financial measure, was $(3.5) million for Q2 2026 compared to $(1.7) million, and $(5.2) million for YTD 2026 compared

to $(2.4) million. Net loss, the most directly comparable GAAP measure, is presented above. See “Non-GAAP Financial Measures”

below and the reconciliation of net loss to Adjusted EBITDA in the financial tables accompanying this press release.

Financial

Condition

of June 30, 2026, cash was $14.0 million compared to $15.4 million as of December 31, 2025. During Q2 2026, the Company drew $6.5 million

under its existing credit facility with Avenue Capital Group, providing non-dilutive capital following the receipt of FDA clearance for

the DeepView System.

2026

Guidance

The

Company is reiterating revenue of approximately $18.5 million for the year ending December 31, 2026, primarily reflecting the continued

development of the Company’s DeepView System through the BARDA PBS Contract. This guidance does not include any material contributions

from the sale of the DeepView System for the burn indication, which is anticipated by year end 2026, or further extensions or additional

awards of our contract with MTEC.

CONFERENCE

CALL

The

Company will host a conference call today at 5:00 pm Eastern Time to discuss these results. Investors interested in participating in

the live call can dial:

● 833-890-6620

– U.S.

● 412-564-3789

– International

simultaneous webcast of the call may be accessed online from the Events section of the Investor Relations page of the Company’s

website at https://investors.spectral-ai.com/news-events/events.

About

Spectral AI

Spectral

AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound

care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by

“Seeing the Unknown®” with its DeepView System. The DeepView System is a predictive diagnostic device that offers physicians

an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven

results and a goal to exceed the current standard of care, the DeepView System provides fast and accurate treatment insights to improve

patient outcomes and reduce healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies

2025. For more information about the DeepView System, visit www.spectral-ai.com.

Non-GAAP

Financial Measures

This

release contains Adjusted EBITDA, a financial measure that is not calculated in accordance with generally accepted accounting principles

in the United States (“GAAP”). The Company defines Adjusted EBITDA as net loss before income taxes, depreciation of property

and equipment and net interest expense, further adjusted to exclude stock-based compensation, financing related costs, changes in the

fair value of warrant liabilities and notes payable, foreign exchange transaction gains and losses, and transaction costs.

Management

uses Adjusted EBITDA to evaluate the Company’s operating performance, identify trends, prepare budgets and financial projections,

and allocate resources. The Company believes Adjusted EBITDA is useful to investors because it excludes items that management does not

consider indicative of core operating performance — principally non-cash remeasurements of the fair value of the Company’s

warrant liabilities, which can fluctuate significantly from period to period based on the Company’s share price and are outside

management’s control — thereby facilitating comparisons between periods and with other companies that report similar measures.

The Company also excludes stock-based compensation because it is a non-cash expense whose amount in any period reflects the timing and

size of equity awards and valuation inputs such as the Company’s share price at the date of grant, rather than the Company’s

underlying operating activities, and can therefore vary significantly from period to period.

Adjusted

EBITDA has limitations as an analytical tool and should not be considered in isolation, or as a substitute for or superior to net loss

or any other measure prepared in accordance with GAAP. Among other limitations, Adjusted EBITDA excludes net interest expense, which

represents a recurring cash cost of the Company’s borrowings; excludes income taxes; excludes stock-based compensation, which is

a recurring non-cash expense the Company expects to continue to incur and which is an important component of employee compensation; and

does not reflect capital expenditures, working capital requirements or other cash requirements. Adjusted EBITDA is a performance measure

and should not be construed as a measure of liquidity or of the cash flows generated by the Company’s operating, investing or financing

activities. Because non-GAAP measures are not standardized, the Company’s Adjusted EBITDA may not be comparable to similarly titled

measures reported by other companies.

reconciliation of net loss, the most directly comparable GAAP measure, to Adjusted EBITDA is included in the financial tables accompanying

this release.

Forward-Looking

Statements

Certain

statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions

of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans,

objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,”

“expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,”

“seeks,” “may,” “will,” “should,” “future,” “propose” and variations

of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking

statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of

known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that

could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers

are cautioned not to place undue reliance on any forward-looking statements.

Investors

should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections

of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K

for the year ended December 31, 2025 and the other documents filed by the Company. These filings identify and address other important

risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Investors:

The

Equity Group

Devin

Sullivan, Managing Director

Devin.Sullivan@theequitygroup.com

Conor

Rodriguez, Associate

Conor.Rodriguez@theequitygroup.com

Spectral

AI, Inc.

Unaudited

Condensed Consolidated Balance Sheets

(in

thousands, except share and per share data)

June 30,

December 31,

2026

2025

(unaudited)

Assets

Current assets:

Cash and cash equivalents

$ 13,980

$ 15,394

Accounts receivable, net

1,181

1,267

Inventory

815

838

Prepaid expenses

494

821

Other current assets

1,322

1,133

Total current assets

17,792

19,453

Non-current assets:

Property and equipment, net

198

258

Right-of-use assets

1,109

1,407

Other assets

337

287

Total Assets

$ 19,436

$ 21,405

Liabilities and Stockholders’ Deficit

Current liabilities:

Accounts payable

$ 1,725

$ 3,010

Accrued expenses

1,708

2,341

Deferred revenue

154

Lease liabilities, short-term

776

734

Notes payable

3,859

2,854

Warrant liabilities

11,780

11,533

Total current liabilities

19,869

20,626

Notes payable, long-term

11,055

5,538

Lease liabilities, long-term

566

968

Total Liabilities

31,490

27,132

Commitments and contingencies

Stockholders’ Deficit

Preferred stock ($0.0001 par value); 1,000,000 shares authorized; no shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively

—

Common stock ($0.0001 par value); 80,000,000 shares authorized; 32,184,928 and 30,688,895 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively

Additional paid-in capital

51,302

50,030

Accumulated other comprehensive income

Accumulated deficit

(63,388 )

(55,800 )

Total Stockholders’ Deficit

(12,054 )

(5,727 )

Total Liabilities and Stockholders’ Deficit

$ 19,436

$ 21,405

Spectral

AI, Inc.

Unaudited

Condensed Consolidated Statements of Operations

(in

thousands, except share and per share data)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Research and development revenue

$ 3,524

$ 5,065

$ 7,515

$ 11,772

Cost of revenue

(2,411 )

(2,775 )

(4,375 )

(6,314 )

Gross profit

1,113

2,290

3,140

5,458

Operating expenses:

Research and development

1,696

1,457

3,258

2,770

General and administrative

3,088

2,616

5,316

5,061

Selling and marketing

653

340

861

646

Total operating expenses

5,437

4,413

9,435

8,477

Operating loss

(4,324 )

(2,123 )

(6,295 )

(3,019 )

Other income (expense):

Net interest expense

(378 )

(397 )

(815 )

(417 )

Financing related costs

(5 )

(4 )

(12 )

(585 )

Change in fair value of warrant liability

711

(5,449 )

(291 )

(1,196 )

Change in fair value of notes payable

—

220

Foreign exchange transaction loss, net

(10 )

(14 )

(15 )

(22 )

Total other income (expense), net

318

(5,864 )

(1,133 )

(2,000 )

Loss before income taxes

(4,006 )

(7,987 )

(7,428 )

(5,019 )

Income tax provision

(170 )

(160 )

(52 )

Net loss

$ (4,176 )

$ (7,968 )

$ (7,588 )

$ (5,071 )

Net loss per share of common stock

Basic

$ (0.13 )

$ (0.31 )

$ (0.24 )

$ (0.21 )

Diluted

$ (0.13 )

$ (0.31 )

$ (0.24 )

$ (0.21 )

Weighted-average common shares outstanding

Basic

32,080,874

25,421,560

31,922,459

24,409,550

Diluted

32,080,874

25,421,560

31,922,459

24,409,550

Other comprehensive income (loss):

Foreign currency translation adjustments

$ (1 )

$ 32

$ (11 )

$ 49

Total comprehensive loss

$ (4,177 )

$ (7,936 )

$ (7,599 )

$ (5,022 )

Beginning

on April 1, 2026, the Company changed the presentation of certain costs on its condensed consolidated statements of operations. This

voluntary change in classification of certain research and development and selling and marketing costs resulted in a decrease in general

and administrative expenses and offsetting increases in research and development and selling and marketing costs. This change in classification

has been applied retrospectively to all periods presented and had no impact to revenue, cost of revenue, loss from operations, income

(loss) before income taxes, income tax provision (benefit), net income (loss), earnings (loss) per common share, or other components

of equity or cash flows.

Spectral

AI, Inc.

Unaudited

Condensed Consolidated Statements of Cash Flows

(in

thousands)

Six Months Ended

June 30,

2026

2025

Cash flows from operating activities:

Net loss

$ (7,588 )

$ (5,071 )

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation expense

Amortization of debt issuance costs

339

120

Stock-based compensation

990

611

Amortization of right-of-use assets

298

280

Change in fair value of warrant liabilities

291

1,196

Change in fair value of notes payable

—

(220 )

Issuance of shares for borrowing related costs

—

241

Changes in operating assets and liabilities:

Accounts receivable

1,038

Inventory

(37 )

Prepaid expenses

327

355

Other assets

(239 )

132

Accounts payable

(1,285 )

(2,049 )

Accrued expenses

(634 )

(663 )

Deferred revenue

(133 )

(536 )

Lease liabilities

(360 )

(276 )

Net cash used in operating activities

(7,825 )

(4,867 )

Cash flows from financing activities:

Proceeds from issuance of common stock and warrants

3,080

Proceeds from notes payable

6,500

8,260

Payments for notes payable

(317 )

(1,313 )

Proceeds from warrant exercises

—

Stock option exercises

180

158

Net cash provided by financing activities

6,422

10,185

Effect of exchange rate changes on cash

(11 )

Net increase (decrease) in cash

(1,414 )

5,367

Cash, beginning of period

15,394

5,157

Cash, end of period

$ 13,980

$ 10,524

Supplemental cash flow information:

Cash paid for interest

$ 587

$ 11

Cash paid for taxes

$ 44

$ 1

Noncash investing and financing activities disclosure:

Tenant improvement allowance payments made by the lessor directly to a third party

$ —

$ (327 )

Issuance of common stock to settle notes payable

$ —

$ 1,192

Spectral

AI, Inc.

Reconciliation

of Net Loss to Adjusted EBITDA (Non-GAAP)

(in

thousands)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Net loss

$ (4,176 )

$ (7,968 )

$ (7,588 )

$ (5,071 )

Adjust:

Depreciation expense

Provision for income taxes

170

(19 )

160

Net interest expense

378

397

815

417

EBITDA

(3,598 )

(7,580 )

(6,553 )

(4,590 )

Additional adjustments:

Stock-based compensation

807

411

990

611

Financing related costs

585

Change in fair value of warrant liability

(711 )

5,449

291

1,196

Change in fair value of notes payable

—

(220 )

Foreign exchange transaction loss, net

Adjusted EBITDA

$ (3,487 )

$ (1,702 )

$ (5,245 )

$ (2,396 )

GRAPHIC

Filename: ea030180701_ex99-1img1.jpg · Sequence: 3

Binary file (11197 bytes)

Download ea030180701_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Aug. 11, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 11, 2026

Entity File Number

001-40058

Entity Registrant Name

SPECTRAL AI, INC.

Entity Central Index Key

0001833498

Entity Tax Identification Number

85-3987148

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2515 McKinney Avenue

Entity Address, Address Line Two

Suite 1000

Entity Address, City or Town

Dallas

Entity Address, State or Province

Entity Address, Postal Zip Code

75201

City Area Code

972

Local Phone Number

499-4934

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock, par value $0.0001 per share

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

MDAI

Security Exchange Name

NASDAQ

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $2.75 per share

Title of 12(b) Security

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $2.75 per share

Trading Symbol

MDAIW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=MDAI_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=MDAI_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf2.75PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: